Showing results (51-60 of 63) with videos related to

Sort By:
Pageof 7
Clinical Hematology International|March 20, 2020
Timed sequential salvage chemotherapy for relapsed or refractory acute myeloid leukemiaBogdan Popescu, Sheenu Sheela, Julie Thompson, et al.
Pharmacoeconomics|December 6, 2018
Q-TWiST Analysis to Assess Benefit-Risk of Pembrolizumab in Patients with PD-L1-Positive Advanced or Metastatic Non-small Cell Lung CancerMin Huang, M Catherine Pietanza, Ayman Samkari, et al.
Cancer Causes & Control : CCC|September 18, 2015
Associations between sociodemographic and clinicopathological factors and breast cancer subtypes in a population-based studyAdana A M Llanos, Sheenu Chandwani, Elisa V Bandera, et al.
Environmental Monitoring and Assessment|July 3, 2024
Disturbance and vegetational structure in an urban forest of Indian Siwaliks: an ecological assessmentAbhishek Kumar, Pardeep Kumar, Meenu Patil, et al.
Vaccine|September 3, 2019
Introducing rotavirus vaccine in the Universal Immunization Programme in India: From evidence to policy to implementationAkash Malik, Pradeep Haldar, Arindam Ray, et al.
ACS Medicinal Chemistry Letters|October 22, 2015
Design, Synthesis, and Biological Evaluation of 1,2-Dihydroisoquinolines as HIV-1 Integrase InhibitorsVibha Tandon, Urvashi, Pooja Yadav, et al.
Scientific Reports|January 6, 2017
Identification of Guanosine 5'-diphosphate as Potential Iron Mobilizer: Preventing the Hepcidin-Ferroportin Interaction and Modulating the Interleukin-6/Stat-3 PathwayStanzin Angmo, Neha Tripathi, Sheenu Abbat, et al.
Alimentary Pharmacology & Therapeutics|July 16, 2025
The Magnitude of Polypharmacy and Role of Disease Severity and Patient Sex in Medication Use Among Patients With MASLD Enrolled in TARGET-NASHBrent A Neuschwander-Tetri, Heather L Morris, Andrea R Mospan, et al.
Immunotherapy|June 2, 2021
Real-world effectiveness of pembrolizumab in advanced melanoma: analysis of a French national clinicobiological databaseEmilie Casarotto, Sheenu Chandwani, Laurent Mortier, et al.
Pharmacoeconomics - Open|September 19, 2019
Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong KongHerbert H Loong, Carlos K H Wong, Linda Kam Suet Leung, et al.
Pageof 7